A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Netherton syndrome (NS) is a rare autosomal recessive disease and no systemic treatment or standard of care currently exists for patients with NS. DS-2325a, a specific and potent inhibitor of kallikrein 5, is expected to treat NS by replacing a defective gene.
Epistemonikos ID: 6d162958d4324859f4e7af4a507a695039998438
First added on: May 13, 2024